Cancer Pharmacologist and HTS Scientist

项目总结： 范德比尔特-英格拉姆癌症中心(VICC)是美国国家癌症研究所指定的综合性癌症中心，拥有超过 270名成员专注于与癌症相关的研究。范德比尔特化学生物学研究所(VICB) 建立了吞吐量筛选(HTS)核心设施，以提供基于筛选的服务 分子探测器发现的调查人员。约书亚·鲍尔博士在两国之间的关系中发挥着不可或缺的作用 范德比尔特大学的癌症研究和化学生物学项目。他在癌症方面有很强的背景 生物学、药理学和生物化学，具有功能基因组和药物筛选经验。他的主要 目标是使用化学基因组方法，包括功能基因组筛选和高含量 成像，以识别新的药物靶点，并更好地了解 肿瘤细胞如何对疗法做出反应。为了实现这个目标，他的癌症相关项目在 HTS设施专注于三个领域：1)化合物文库筛选和其他HTS药物筛选，2) 功能基因组(SiRNA)文库筛选；3)高含量筛选(HCS)和分析。到目前为止，Dr。 鲍尔为50多个HTS项目提供了支持和智力贡献，包括与 至少19名癌症中心成员，包括13名由NCI资助的成员。持续的合作与 癌症研究人员使他能够开发创新的分析方法和新的筛查项目，这些项目对 为范德比尔特高温超导核心和癌症研究计划的成功干杯。他的重要角色和成功源于 从他协作、设计和执行屏幕的能力，以及为项目做出智力贡献的能力，授予 提案和手稿。此外，通过参加各种会议和研讨会，Dr。 鲍尔致力于将最先进的技术和理念带到范德比尔特高温超导工厂。他的混合体 技能、专业知识和知识在范德比尔特公司中发挥着独特的作用，可以修补癌症研究、化学物质 生物学、基因组学、药物发现和转译药物研究。鲍尔博士的巨蟹座角色 药理学家和HTS科学家是范德比尔特癌症研究项目不可或缺的一员。

Project Summary: The Vanderbilt-Ingram Cancer Center (VICC) is an NCI-designated Comprehensive Cancer Center with over 270 members focused on cancer-related research. The Vanderbilt Institute of Chemical Biology (VICB) High- Throughput Screening (HTS) core facility was established to provide screening-based services with investigators for molecular probe discovery. Dr. Joshua Bauer plays an integral role in the interface between the cancer research and chemical biology programs at Vanderbilt. He has a strong background in cancer biology, pharmacology, and biochemistry with functional genomic and drug screening experience. His main goal is to use chemical genomic approaches, including functional genomic screening and high-content imaging, to identify novel drug targets and to better understand the molecular and genetic mechanisms that underlie how cancer cells respond to therapeutics. To achieve this goal his cancer-related projects within the HTS facility are focused on three areas: 1) compound library screening and other HTS drug screening, 2) functional genomic (siRNA) library screening, and 3) high-content screening (HCS) and analysis. To date, Dr. Bauer has provided support and intellectual contributions to over 50 HTS projects, including collaborations with at least 19 Cancer Center members, including 13 that are NCI funded. The continued collaborations with cancer investigators has allowed him to develop innovative assays and novel screening projects that contribute to the success of the Vanderbilt HTS core and cancer research program. His vital role and success stems from his ability to collaborate, design and perform screens, and intellectually contribute to projects, grant proposals, and manuscripts. In addition, through participation in conferences, meetings and workshops Dr. Bauer strives to bring state-of-the-art technologies and ideas to the Vanderbilt HTS facility. The blend of his skills, expertise, and knowledge provide a unique role within Vanderbilt to mend cancer research, chemical biology, genomics, drug discovery, and translational drug investigation. Dr. Bauer's role as a Cancer Pharmacologist & HTS Scientist is completely indispensable to the cancer research program at Vanderbilt.